270 related articles for article (PubMed ID: 31253631)
1. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.
Kamran SC; Lennerz JK; Margolis CA; Liu D; Reardon B; Wankowicz SA; Van Seventer EE; Tracy A; Wo JY; Carter SL; Willers H; Corcoran RB; Hong TS; Van Allen EM
Clin Cancer Res; 2019 Sep; 25(18):5561-5571. PubMed ID: 31253631
[TBL] [Abstract][Full Text] [Related]
2. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
[TBL] [Abstract][Full Text] [Related]
3. Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy.
Yang J; Lin Y; Huang Y; Jin J; Zou S; Zhang X; Li H; Feng T; Chen J; Zuo Z; Zheng J; Li Y; Gao G; Wu C; Tan W; Lin D
Theranostics; 2019; 9(23):6856-6866. PubMed ID: 31660073
[TBL] [Abstract][Full Text] [Related]
4. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
[TBL] [Abstract][Full Text] [Related]
6. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
[TBL] [Abstract][Full Text] [Related]
7. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
8. Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
Wilkins A; Fontana E; Nyamundanda G; Ragulan C; Patil Y; Mansfield D; Kingston J; Errington-Mais F; Bottomley D; von Loga K; Bye H; Carter P; Tinkler-Hundal E; Noshirwani A; Downs J; Dillon M; Demaria S; Sebag-Montefiore D; Harrington K; West N; Melcher A; Sadanandam A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33678606
[TBL] [Abstract][Full Text] [Related]
9. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
10. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
11. Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response.
Lee TH; Jang BS; Chang JH; Kim E; Park JH; Chie EK
Cancer Med; 2023 Jul; 12(14):15664-15675. PubMed ID: 37260182
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
El Otmani I; El Agy F; El Baradai S; Bouguenouch L; Lahmidani N; El Abkari M; Benajah DA; Toughrai I; El Bouhaddouti H; Mouaqit O; Ibn Majdoub Hassani K; Mazaz K; Benjelloun EB; Ousadden A; El Rhazi K; Bouhafa T; Benbrahim Z; Ouldim K; Ibrahimi SA; Ait Taleb K; Chbani L
Dis Markers; 2020; 2020():8459303. PubMed ID: 31998419
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
15. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Mouw KW; Cleary JM; Reardon B; Pike J; Braunstein LZ; Kim J; Amin-Mansour A; Miao D; Damish A; Chin J; Ott PA; Fuchs CS; Martin NE; Getz G; Carter S; Mamon HJ; Hornick JL; Van Allen EM; D'Andrea AD
Clin Cancer Res; 2017 Jun; 23(12):3214-3222. PubMed ID: 27852700
[No Abstract] [Full Text] [Related]
16. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
[TBL] [Abstract][Full Text] [Related]
17. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
[TBL] [Abstract][Full Text] [Related]
19. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions.
Sakai K; Kazama S; Nagai Y; Murono K; Tanaka T; Ishihara S; Sunami E; Tomida S; Nishio K; Watanabe T
Oncotarget; 2014 Oct; 5(20):9641-9. PubMed ID: 25275295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
